Mainz Biomed N.V. (BST: 4TO)
Germany
· Delayed Price · Currency is EUR
6.64
-0.10 (-1.48%)
At close: Dec 5, 2024
Mainz Biomed Revenue
Mainz Biomed had revenue of $260.39K USD in the quarter ending June 30, 2024, with 4.60% growth. This brings the company's revenue in the last twelve months to $917.20K, up 16.23% year-over-year. In the year 2023, Mainz Biomed had annual revenue of $895.48K with 69.00% growth.
Revenue (ttm)
$917.20K
Revenue Growth
+16.23%
P/S Ratio
n/a
Revenue / Employee
$12.92K
Employees
71
Market Cap
9.70M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | 281.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 33.27B |
Siemens Aktiengesellschaft | 75.93B |
Deutsche Telekom AG | 116.87B |
Allianz SE | 97.41B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.99B |
Merck KGaA | 20.96B |
Siemens Healthineers AG | 22.36B |
Mercedes-Benz Group AG | 147.95B |
Mainz Biomed News
- 2 days ago - Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewsWire
- 8 days ago - EQS-News: Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Wallstreet:Online
- 8 days ago - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Wallstreet:Online
- 8 days ago - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - GlobeNewsWire
- 5 weeks ago - Quest Diagnostics deal sends Mainz higher - Seeking Alpha
- 5 weeks ago - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - GlobeNewsWire
- 5 weeks ago - EQS-News: Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Wallstreet:Online
- 6 weeks ago - Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewsWire